Posts by tag
KRAS mutations
1 post
Daraxonrasib: A Turning Point for Pancreatic Cancer
Pancreatic ductal adenocarcinoma remains one of the most difficult cancers to treat, with limited progress in drug development over the past decade. At the 2026 ASCO Annual Meeting, the Phase 3 RASolute 302 trial delivered results that stood out against…